Cannabis Law Report

JULY 19, 2021

RYAH is a recognized leader in dose control technology for plant-based medicine, and we are pleased to be in a position to support the study and establish a new standardization of monitoring and measuring inhalation therapies in plant-based medicines,” said Gabriella Roda, researcher at the Department of Pharmaceuticals at the University of Milan.

Therapy 76

Therapy Data Research and Development Pharmaceutical 76

Veriheal

JUNE 29, 2022

Consequently, psychedelics have received a significant amount of attention for ailments that are in need of more effective solutions, such as treatment-resistant depression (TRD). Exploring Psilocybin and Treatment-Resistant Depression. Earlier this year, psilocybin was investigated as a means of assisting with TRD.

Clinical Trials 105

Clinical Trials Blood Pressure Treatment Therapy 105

Veriheal

APRIL 18, 2024

Their results were promising, as they found that CBD resulted in better treatment outcomes and fewer side effects than traditional medications. In addition, CBD stands out primarily for presenting mild adverse events, the main complaints associated with the use of usual psychotropic drugs.”

Treatment 59

Treatment CBD Chronic Pain Events 59

Cannabis Law Report

JULY 24, 2021

“The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

JUNE 28, 2021

Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. The aim of the agreement is to make medical cannabis treatments available to patients, with an initial focus on neurological therapies. It is expected to be worth USD 2.1

Access 105

Access Research and Development Pharmaceutical Therapy 105

Cannabis Law Report

OCTOBER 20, 2021

International Summit on Psychedelic Therapies for Mental Illness 17-20 November 2021. The event will also feature a two-day pre-Summit Introductory Workshop Program (17-18 November) led by Nigel Denning, Dr Tra-ill Dowie with world-leading therapist trainer Dr Bill Richards (USA) from Johns Hopkins University.

Therapy 52

Therapy Medicine Topical Events 52

Cannabis Law Report

JULY 22, 2021

As regulations develop, the next phase of the Company’s strategy will involve the inclusion of alternative and psychedelic therapies into Levitee’s platform of traditional healthcare assets. About Levitee Labs. Levitee Labs is establishing itself as a leader in the integrative wellness space.

eCommerce 105

eCommerce Therapy Media Access 105

Cannabis Law Report

JULY 21, 2021

The treatment is designed to target nociplastic pain originating in the central nervous system through the neuroplasticity benefits of psilocybin. “Existing treatment options for fibromyalgia are often ineffective and show significant side effects,” said Daniel Clauw, M.D.,

Clinical Trials 105

Clinical Trials Chronic Pain Research and Development Treatment 105

MMJ Recs

JULY 11, 2024

Medical marijuana is a potential treatment for insomnia, and it offers an alternative to traditional pharmaceuticals. It is often caused by life events such as stress, anxiety, or a significant change in routine. Chronic insomnia often requires a more comprehensive treatment approach.

Sleep 111

Sleep Treatment Research and Development Therapy 111

Cannabis Law Report

JANUARY 26, 2022

MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021. The Innovative Licensing and Access Pathway (ILAP) Innovation Passport has ben granted to MDMA as an adjunct to therapy for posttraumatic stress disorder (PTSD) in the United Kingdom (UK).

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

SpeedWeed

MARCH 26, 2021

That’s just one step being taken to prepare the state for the eventual implementation of Measure 109, in which 56 percent of voters approved last fall to legalize psychedelic mushroom therapy. . I’m a Black woman and I care about making these treatments relevant to my community,” Hagens said in a press statement. “I

Therapy 52

Therapy Education Legalization Media 52

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Miss Marijuana

JULY 6, 2025

It’s a mental health problem that can happen to anyone after a scary or shocking event. Conventional Treatments for PTSD So, what do people usually do to feel better? This is called “talk therapy,” and it helps people work through their feelings. But here’s the thing: not everyone feels better with these treatments.

Patients 52

Patients Sleep Cannabis Therapy 52

Cannabis Law Report

NOVEMBER 26, 2019

In Canada today, close to 70% of all those surveyed aged 19+ believe that cannabis is an alternate form of treatment to some medical conditions according to Vividata’s Vivintel , the nation’s largest syndicated cannabis consumer study. We are partnering with Canopy Growth to offer a unique event of fun and canna-learning.

Chronic Pain 91

Chronic Pain Events THC Education 91

United Patients Group

DECEMBER 5, 2023

So, whether you’re a patient looking for alternatives, a caregiver seeking new treatment options, or a curious mind interested in the intersection of cannabis and mental health, this discussion is for you. Let’s journey together into the promising world of medical cannabis and its potential for mental health treatment.

Research and Development 105

Research and Development Treatment Patients Conditions 105

The Cannigma

OCTOBER 21, 2021

Simon is not alone, one study reviewed online forum posts about cannabis and ADHD and found that 25% of posts indicated therapeutic benefits from this treatment – with statements like “While you are high … you will be able to focus much, much better than you normally would” and “(cannabis) helps me greatly with my ADHD.”

Blood Pressure 137

Blood Pressure Treatment Patients Cannabis 137

Project CBD

DECEMBER 31, 2022

In recent years, psilocybin and MDMA have been explored as potential treatments for post-traumatic stress disorder, but somewhat more quietly so has cannabis. Adverse events related to cannabis use were predominately mild or moderate, with insomnia and fatigue being most common at 20 incidents each.

Sleep 130

Sleep Patients Treatment Cannabis 130

Veriheal

JUNE 30, 2023

To start, participants reported that psilocybin had helped them process emotions tied to painful events in their past. Additionally, participants also reported feeling increased self-awareness and general improvement in relationships following their treatment. The Summit found that cannabis does not enhance athletic performance.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

CannaMD

MAY 25, 2021

These findings could point to new cannabis-based therapies for both the healing of broken bones and the slowing of degenerative osteoporosis. These findings might indicate that cannabis therapies with a higher CBD content would prove more beneficial for bone healing and regrowth. THC, CBD & THE ECS. Find Out if You Qualify.

Marijuana 111

Marijuana Research and Development Clinical Trials THC 111

The Joint Blog

APRIL 17, 2020

This study summarizes potential adverse drug events related to THC when combined with other medications Medicinal Use of Marijuana Cannabis has been used widely across North America in various state or provincial medical marijuana programs. Diminishing efficacy of these receptors over time should be considered for proper treatment.

Events 48

Events THC Chronic Pain Conditions 48

The Joint Blog

MARCH 3, 2021

The study is titled Medical cannabis for the treatment of fibromyalgia syndrome: A retrospective, open-label case series. in a cohort of 38 patients with treatment-resistant fibromyalgia. The study found “significant improvements were observed” following the initiation of cannabis therapy in most patients. Conclusions.

Therapy 61

Therapy Hybrid Marijuana Research and Development 61

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients 98

Patients Education Marijuana Therapy 98

LifeCannMD

MAY 27, 2025

Now, with 1.5mg of a balanced THC:CBD tincture twice daily, he’s giving presentations at work and actually enjoying social events again. times more likely to achieve their treatment goals with medical cannabis. He’s now able to attend his daughter’s school events without panic attacks.

Microdosing 52

Microdosing Research and Development Sleep Chronic Pain 52

Cannabis Law Report

SEPTEMBER 15, 2021

This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. The FDA has received adverse event reports involving delta-8 THC-containing products. brownies, gummies).

THC 105

THC Pets Events Hemp 105

Cannabis Law Report

JULY 27, 2021

The longitudinal study showed that individuals who used artisanal cannabidiol (CBD) products reported better quality of life, lower psychiatric symptom severity and fewer medication-related adverse events compared with those not using CBD. This study represents a refreshing collaboration of scientists, clinicians, patients and advocates.

Data 81

Data Epilepsy Research and Development Clinical Trials 81

Cannabis Law Report

JUNE 23, 2021

. “We are excited to be initiating our pilot program with Medicann in Jersey, which represents a unique, ‘ring-fenced’ environment for establishing potentially numerous studies on the efficacy of treatments using plant-based therapies.

Programs 100

Programs Data Events Collective 100

Cannabis Law Report

JUNE 4, 2021

The unique properties of 225Ac-J591 suggest it as a very promising candidate for combination treatment with beta emitters, whereby the synergy of therapeutic isotope combination and broader tumor effect would have the potential to further shape theragnostic platforms.” PSA declines and CTC responses were clearly evident.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

JUNE 14, 2022

Those values guide our joint efforts to change perceptions about psychedelic assisted therapies, raise awareness of the scientific advances and, ultimately, bring better health to European citizens. Ketamine is already registered for the treatment of depression and in 2023, the FDA might approve an MDMA assisted therapy for PTSD.

Access 52

Access Therapy Clinical Trials Treatment 52

Cannabis Law Report

JULY 7, 2021

is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. KetamineOne Capital Limited (formerly Myconic Capital Corp.) On behalf of: KETAMINE ONE.

Research and Development 98

Research and Development Treatment Therapy Banking 98

The Joint Blog

DECEMBER 23, 2019

No adverse events were reported in this study”, states the study. The treatment product was well-tolerated and may provide a more effective alternative compared to other current therapies in the treatment of peripheral neuropathy.” No adverse events were reported in this study. males and 37.9%

Topical 49

Topical CBD Therapy Treatment 49

Cannabis Law Report

JULY 28, 2021

To date, the clinic network has seen over 75,000 unique patients and has conducted extensive research in cannabinoid therapy as it relates to sleeping disorders, opioid reduction and other topics. is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

MARCH 2, 2020

Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to Compass Pathways ‘ psilocybin therapy for treatment-resistant depression. A few months later, the agency awarded BTD for Usona Institute ‘s psilocybin therapy for major depressive disorder. Then, something strange happened.

Medicine 59

Medicine Therapy DEA Pharmaceutical 59

Medicinal Genomics

APRIL 9, 2025

Many cannabis cultivators have successfully eliminated HLVd and boosted yields with early detection through qPCR testing, in addition to rigorous sanitation treatments. The volume of water used in a single irrigation event is referred to as “shot size” and it is frequently expressed as a percentage of the overall substrate volume.

Environment 69

Environment Cultivation Research and Development Terpenes 69

Cannabis Law Report

JUNE 19, 2022

A new alliance aiming to help hone the therapeutic potential of psychedelics is set to emerge from Europe, making its debut via a virtual event later this month. The group advocates the urgent need for psychedelics, citing that mental health has become a serious societal crisis because we are lacking sufficient treatment options.

Therapy 52

Therapy Advocacy Events Treatment 52

Cannabis Law Report

AUGUST 25, 2021

Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 85

Clinical Trials Research and Development Therapy Conditions 85

Veriheal

FEBRUARY 28, 2021

It helps to showcase the 103 countries holding events on this day as well as the thousands of events hosted online worldwide. This year, COVID-19 has dramatically impacted the way events are hosted. Instead of having physical locations, many events have opted to go digital being held online.

Chronic Pain 52

Chronic Pain Events Therapy Treatment 52

Puff Puff Post

MARCH 10, 2020

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. With enrollment completed, treatment is expected to conclude towards the end of March and results are anticipated to be announced in the second half of calendar 2020.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84